Coya Therapeutics’ (COYA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a report released on Monday morning,Benzinga reports. The brokerage currently has a $18.00 price objective on the stock. HC Wainwright also issued estimates for Coya Therapeutics’ Q4 2024 earnings at ($0.32) EPS, FY2024 earnings at ($1.13) EPS, Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.50) EPS, Q4 2025 earnings at ($0.52) EPS and FY2025 earnings at ($1.68) EPS.

Separately, Chardan Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research report on Thursday, November 7th.

Coya Therapeutics Price Performance

COYA opened at $6.81 on Monday. The business has a fifty day moving average price of $7.11 and a 200 day moving average price of $7.01. Coya Therapeutics has a 12 month low of $4.75 and a 12 month high of $10.69. The stock has a market capitalization of $113.80 million, a price-to-earnings ratio of -10.48 and a beta of 0.46.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.15. On average, research analysts anticipate that Coya Therapeutics will post -1.27 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Arun Swaminathan purchased 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were purchased at an average cost of $7.34 per share, for a total transaction of $36,700.00. Following the purchase, the chief executive officer now directly owns 5,000 shares of the company’s stock, valued at $36,700. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders acquired a total of 9,510 shares of company stock worth $69,615 over the last 90 days. 12.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Coya Therapeutics

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Coya Therapeutics by 772.3% in the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock valued at $8,407,000 after purchasing an additional 750,338 shares during the last quarter. GHP Investment Advisors Inc. acquired a new position in Coya Therapeutics during the third quarter worth approximately $169,000. Renaissance Technologies LLC purchased a new stake in Coya Therapeutics in the second quarter valued at approximately $101,000. Finally, Gilbert & Cook Inc. acquired a new stake in shares of Coya Therapeutics in the second quarter valued at approximately $61,000. Hedge funds and other institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.